top of page

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

5 September 2023


ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research and development activities using CRISPR/Cas9.


Dublin, Ireland and Nice, France, September 5: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with AlgenScribe SAS (‘AlgenScribe’). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.


ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.


AlgenScribe, headquartered in Nice, is a biotechnology company developing a genome editing platform to improve human health. This platform possesses unique abilities to increase the efficiency of homologous recombination and addresses limitations related to nuclease-based genome editing. The company mission is to translate technologies into therapeutics.


Commenting on the deal, Frédéric Zampatti, CEO of AlgenScribe stated:This license from ERS enables us to access the CRISPR IP portfolio which will be used in combination with our own platform. This will allow us to show synergies in different applications within a known legal framework.”


Eric Rhodes, CEO, ERS Genomics was enthusiastic about the new relationship: ‘AlgenScribe’s mission of ‘technologies into therapeutics’ resonates with our commitment to propel scientific advancement by enabling CRISPR/Cas9 accessibility. Witnessing the practical influence of our technology within our industry is a significant goal for us. We’re genuinely excited to see what AlgenScribe has in store for the future.’


Financial details of the agreement are not being disclosed.

Posts récents

Voir tout

Comments


bottom of page